CPRX: Catalyst Pharmaceutical Inc. Company Profile & Statistics

About

Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.?The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.?Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.

Info & Links

CEO

Richard J. Daly

Headquarters

355 ALHAMBRA CIRCLE,SUITE 801
CORAL GABLES, FL 33134, UNITED STATES

Auditor

GRANT THORNTON LLP

Share holders

Employees

167

Catalyst Pharmaceutical Inc. Statistics

Valuation Measures

Market Capitalization²

2.65B

Enterprise Value

2.21B

Enterprise Value/EBITDA(ttm)

10.44

Price to Earnings Ratio(ttm)

11.92

Price to Sales(ttm)

5.71

Price to Book(mrq)

3.96

Price to Cash(ytd)

10.72

Profitability

Gross Margin(ttm)

86.12%

Operating Margin(ttm)

49.13%

Profit Margin(ttm)

32.60%

Return on Equity(ttm)

40.79%

Return on Invested Capital(ttm)

25.18%

Return on Assets(ttm)

34.87%

Income Statement

Revenue(ttm)

460.48M

Revenue Per Share(ttm)

3.86

Gross Profit(ttm)

397.47M

EBITDA(ttm)³

211.43M

Net Income Available to Common(ttm)

142.80M

Diluted EPS(ttm)

1.18

Share Statistics

Beta (5Y Monthly)

0.80

52-Week Change

31.97%

S&P 500 52-Week Change

12.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

119.27M

Dividend Yield

0.00%

Float⁴

106.15M

% Held by Insiders

11.00%

% Held by Institutions

79.22%

Balance Sheet

Total Cash(mrq)

442.33M

Total Cash Per Share(mrq)

3.71

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

5.17%

Quick Ratio(mrq)

4.92%

Book Value Per Share(mrq)

6.02

Cash Flow

Operating Cash Flow Per Share(ytd)

1.92

Free Cash Flow(ytd)

239.25M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

CPRX

Catalyst Pharmaceutical Inc.

Catalyst Pharmaceutical Inc. Profile